Skip to main content
SpringerLink
Log in

Long-Acting Progestin Injectables

Comparison ofDepo-Provera® With Depo-SubQProvera 104™

  • Chapter
The Handbook of Contraception

Part of the book series: Current Clinical Practice ((CCP))

Abstract

Depo-Provera® (depot medroxyprogesterone acetate [DMPA]) is an extremely effective contraceptive agent. Since its introduction into the market in the 1960s, DMPA has been used for a variety of gynecological conditions including endometriosis and abnormal menstrual bleeding. For many years, DMPA was also commonly used “off-label“ as a contraceptive agent, especially in women who were not candidates for oral contraceptive (OC) pills. In 1992, the Food and Drug Administration (FDA) approved the marketing of DMPA as a contraceptive agent.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ortiz A, Hirol M, Stanczyk FZ, et al. (1977) Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 44:32–38.

    Article  PubMed  CAS  Google Scholar 

  2. Mishell DR Jr, Kharma KM, Thorneycroft IH, et al. (1972) Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 113:372–376.

    PubMed  Google Scholar 

  3. Mishell DR Jr. (1996) Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41:381–390.

    PubMed  CAS  Google Scholar 

  4. Croxatto HG. (2002) Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 65:21–27.

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization Expanded Programme of Research, Development and Research Training in Human Reproduction Task Force on Long-Acting-Systemic Agents for the Regulation of Fertility. (1983) Multinational comparative clinical evaluation of two longacting injectable contraceptive steroids: Norethisterone enanthate and medroxyprogesterone acetate final report. Contraception 18:1.

    Google Scholar 

  6. Cullins VE. (1996) Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 41:428–433.

    PubMed  CAS  Google Scholar 

  7. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. (1991) Depot medroxyprogestonre acetate and the risk of endometrial cancer. Int J Cancer 49:186–190.

    Google Scholar 

  8. Sullivan MG. (2005) New treatment approved for endometriosis. OB Gyn News May 1.

    Google Scholar 

  9. Mattson RH, Cramer JA, Caldwell BVD, et al. (1984) Treatment of seizures with medroxyprogesterone acetate. Preliminary report. Neurology 34:1255–1258.

    CAS  Google Scholar 

  10. Mattson RH, Rebar RN. (1993) Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 168:2027–2032.

    PubMed  CAS  Google Scholar 

  11. Schwallie PC, Assenzo JR. (1973) Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as a intramuscular injection once every 90 days. Fertil Steril 24:331–339.

    PubMed  CAS  Google Scholar 

  12. World Health Organization (WHO). (1990) Injectable contraceptives: their role in family planning. Monograph. Geneva, Switzerland: WHO.

    Google Scholar 

  13. Westhoff C. (1996) Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 41:401–406.

    PubMed  CAS  Google Scholar 

  14. Moore LL, Valuck R, McDougall C, et al. (1995) A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52:25–29.

    Article  Google Scholar 

  15. Polaneczky M, Guarnaccia M, Alon J, Wiley J. (1996) Early experience with the contraceptive use of depo-medroxypgrogesterone acetate in an inner-city population. Fam Plan Perspect 28:174–178.

    Article  CAS  Google Scholar 

  16. Mainwaring R, Hales HA, Stevenson K, et al. (1995) Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 51:149–153.

    Article  PubMed  CAS  Google Scholar 

  17. McCann MF, Potter LS. (1994) Progestin-only contraception: a comprehensive review. Contraception Suppl 50:S1–S195.

    Article  CAS  Google Scholar 

  18. Speroff L, Darney PD. (2001) A Clinical Guide for Contraception, 3rd ed. Philadelphia: Lippincott Williams & Wilkins.

    Google Scholar 

  19. Two-Year Multinational Comparative Trial. (1983) Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone enanthate and medroxyprogesterone acetate final report. Contraception 28:1–20.

    Article  Google Scholar 

  20. Lieu DFM, Ng CSA, Yong YM, et al. (1985) Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51.

    Article  Google Scholar 

  21. Virutamasen P, Wongsrichanalai C, Tangkeo P, et al. (1986) Metabolic defects of depot medroxyprogesterone acetate in long-term users: A cross-sectional study. Int J Gynaecol Obstet 24:291.

    Article  PubMed  CAS  Google Scholar 

  22. Westhoff C. (2003) Depot-medroxyprogesterone acetate injection (Depo-Provera): ahighly effective contraceptive option with proven long-term safety. Contraception 68:75–87.

    Article  PubMed  CAS  Google Scholar 

  23. Kaunitz AM. (2001) Injectable long-acting contraceptives. Clin Obstet Gynecol 44:73–91.

    Article  PubMed  CAS  Google Scholar 

  24. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. (2004) Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103:899–906.

    PubMed  CAS  Google Scholar 

  25. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. (2001) A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 98:576–582.

    Article  PubMed  CAS  Google Scholar 

  26. Banks E, Berrington A, Casabonne D. (2001) Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br J Obstet Gynecol 108:1214–1221.

    Article  CAS  Google Scholar 

  27. Clark MK, Sowers MR, Nichols S, Levy B. (2004) Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fert Steril 82:1580–1586.

    Article  CAS  Google Scholar 

  28. Petitti DB, Piaggio G, Mehta S, et al. (2000) Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. Obstet Gynecol 95:736–744.

    Article  PubMed  CAS  Google Scholar 

  29. Orr-Walker BJ, Evans MC, Ames RW, et al. (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. Clin Endocrinol 49:615–618.

    Article  CAS  Google Scholar 

  30. Scoles D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. (2005) Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159:139–144.

    Article  Google Scholar 

  31. Cromer B A, Lazebnik R, Rome E, et al. (2005) Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 192:42–47.

    Article  PubMed  CAS  Google Scholar 

  32. Cundy T, Ames R, Horne A, et al. (2003) A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 88:78–81.

    Article  PubMed  CAS  Google Scholar 

  33. Kalkwarf HJ, Specker BL. (1995) Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol 86:26–32.

    Article  PubMed  CAS  Google Scholar 

  34. Holmberg-Marttila D, Sievanen H, Laippala P, Tuimala R. (2000) Factors underlying changes in bone mineral during postpartum amenorrhea and lactation. Osteoporos Int 11:570–576.

    Article  PubMed  CAS  Google Scholar 

  35. Polatti F, Capuzzo E, Viazzo F, Colleoni R, Klersy C. (1999) Bone mineral changes during and after lactation. Obstet Gynecol 94:52–56.

    Article  PubMed  CAS  Google Scholar 

  36. Mainwaring R, Hales HA, Stevenson K, et al. (1995) Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 51:149–153.

    Article  PubMed  CAS  Google Scholar 

  37. Moore LL, Valuck R, McDougall C, et al. (1995) A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52:215–219.

    Article  PubMed  CAS  Google Scholar 

  38. Schwallie PC, Assenzo JR. (1974) The effect of depo-progesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 10:181–202.

    Article  PubMed  CAS  Google Scholar 

  39. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. (1991) Breast cancer and depot medroxyprogesterone acetate: a multinational study. Lancet 338:833–838.

    Article  Google Scholar 

  40. Paul C, Skegg DCG, Spears GFS. (1989) Depot medroxyprogestereone (Depo-Provera) and risk of breast cancer. Br Med J 299:759–762.

    Article  CAS  Google Scholar 

  41. Skegg DC, Noonan EA, Paul C, et al. (1995) Depot medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand studies. JAMA 273:799–804.

    Article  PubMed  CAS  Google Scholar 

  42. Mishell DR. (2004) Contraception. In: Strauss J, Barbieri R, eds. Yen and Jaffe’ s Reproductive Endocrinologies. Philadelphia: Elsevier Saunders.

    Google Scholar 

  43. Back DJ, Breckenridge AM, Crawford, FE, et al. (1980) The effects of rifampicin on the pharmacokinetics of ethinyl estradiol in women. Contraception 21:135.

    Article  PubMed  CAS  Google Scholar 

  44. Henzl M. (1993) Evolution of steroids and their contraceptive and therapeutic use. In: Shoupe DS, Haseltine FP, eds. Contraception. New York: Springer-Verlag, pp. 1–16.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Keck School of Medicine at the University of Southern California, Los Angeles, CA

    Ronna Jurow MD

  2. Division of Reproductive Endocrinology and Infertility, Departments of Obstetrics and Gynecology and Family Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA

    Donna Shoupe MD

Authors
  1. Ronna Jurow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna Shoupe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility Departments of Obstetrics and Gynecology and Family Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA

    Donna Shoupe MD

  2. Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA

    Siri L. Kjos MD

  3. Harbor-UCLA Medical Center, Torrance, CA

    Siri L. Kjos MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Jurow, R., Shoupe, D. (2006). Long-Acting Progestin Injectables. In: Shoupe, D., Kjos, S.L. (eds) The Handbook of Contraception. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-150-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-150-5_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-599-6

  • Online ISBN: 978-1-59745-150-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation